Table 4.
Functional outcomes after MAT
| Study (and number of initial patients) | Baseline value (SD) | Endpoint value (SD) | Change (note 1) | p value |
|---|---|---|---|---|
| Lysholm | ||||
| Abat et al. [1] n = 88 | 65.4 (11.6) | 88.6 (7.2) | 23.1 (NR) | < 0.001 |
| Carter et al. [11] n = 40 | 47 (32–68) | 71 (38–95) | 24 (NR) | |
| Cole et al. [13] n = 36 | 52.4 (20.26) | 71.6 (19.7) | 19.2 (NR) | < 0.05 |
| Kim et al. [23] modified Lysholm (n = 110) | 73.2 (10.6) | 89.4 (13.2) | 16.2 (NR) | < 0.001 |
| Marcacci et al. [28] n = 32 | 59.8 (18.3) | 84.8 (14.4) | 25 (NR) | < 0.0001 |
| Saltzman et al. [43] | ||||
| ND (n = 22) | 41.5 (22.3) | NR | 14.8 (14.4)a | NR |
| FTD (69) | 43.4 (17.4) | NR | 21.1 (19.8)a | NR |
| Saltzman et al. [44] MAT + ACL (40) | 44 (16) | 67 (22) | 23 (NR) | < 0.01 |
| Riboh et al. [38] | 43.80 (20.37), n = 30 | 58.52 (17.92), n = 23 | 14.4 (NR) | = 0.03 |
| Rue et al. [42] n = 28 | 48.7 (16.4) | 74.0 (17.7) | 25.3 (NR) | < 0.001 |
| Van der Wal et al. [53] n = 49 | 36.36 (18) | 61.06 (20) | 24.7 (NR) | 0.001 |
| Baseline value (SD or 95% CI) | Endpoint value (SD or 95% CI) | Change (SD) | p value | |
|---|---|---|---|---|
| IKDC | ||||
| Carter et al. [11] n = 40 | 50.6 (32.2–68.9) | 70.1 (39.1–93.1) | 19.5 (NR) | |
| LaPrade et al. [24] n = 40 | 54.5 | 72.0 (n = 34) | 17.5 (NR) | < 0.001 |
| Marcacci et al. [28] n = 32 | 47.4 (20.6) | 77.2 (15.6) | 29.8 (NR) | < 0.0001 |
| Rue et al. [42] n = 28 | 38.7 (12.7) | 66.9 (17.2) | 28.2 (NR) | < 0.001 |
| Saltzman et al. [43] | ||||
| ND, n = 22 | 41.5 (22.3) | NR | 14.8 (14.4) | NR |
| FTD, n = 69 | 43.4 (17.4) | NR | 21.1 (19.8) | NR |
|
Saltzman [44] Concomitant MAT + ACL n = 40 |
44 (16) | 67 (22) | 23 (NR) | < 0.01 |
| Riboh et al. [38] n = 32 (subset of Cole study) | 40.2(19) n = 27 | 65.0 (17.7) n = 23 | 24.8 (NR) | < 0.0001 |
| Stone et al. [48] n = 115 | 45 (n = 66) | 70 (n = 15) | 25 (NR) | < 0.001 |
| Stone et al. [49] n = 49 | Medianb 48 | 75 | 27 (NR) | 0.001 |
| Baseline | Endpoint | p value | |
|---|---|---|---|
| Tegner | |||
| Cole et al. [13] | 5.0 (2.8) | 6.5 (2.7) | < 0.05 |
| González-Lucena et al. [17] | 3.1 (2.1) | 5.5 (2.1) | < 0.001 |
| Marcacci et al. [28] | 3 (IQR 3.5) | 5 (IQR3–6) | 0.012 |
| Rue et al. [42] | 5.0 (3.3) | 6.7 (2.3) | 0.001 |
| Stone et al. [49] (medians) | 2.8 | 5.2 | n.s. |
Note 1: Where papers have not reported changes, these have been calculated but SDs, SEs and CIs are not available
NR not reported by study authors